Multiple Myeloma:  Recognizing Treatment Options

Program Description

The treatment landscape for multiple myeloma (MM) has evolved rapidly in recent years, with an increasing number of therapeutic options associated with unique dosing and administration considerations. Pharmacists must be familiar with emerging drug therapies and optimal sequencing of therapy. This podcast discussion will shed light on the pharmacist’s role in therapy selection for treatment of MM based on patient-specific factors, disease characteristics, and dosing and route of administration.

Target audience: Health System Pharmacist, Oncology Pharmacist, Specialty Pharmacist, Pharmacist Technicians

Type of activity: Application
Release date: July 11, 2022
Expiration date: July 11, 2023

Time to complete activity: 0.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Review systemic treatment options for multiple myeloma (MM) by pharmacologic properties including efficacy, adverse effects, routes of administration, and special considerations for use.
• Outline supportive care measures for patients receiving systemic therapies for MM to mitigate adverse effects.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for .5 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-22-314-H01-P and 0290-0000-22-314-H01-T. The activity is available for CE credit through July 11, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, listen to the podcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Kathryn Maples, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:

Consultant: GlaxoSmithKline, Janssen, Sanofi, Karyopharm

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Meg Taylor, PharmD, CPP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms